Showing results (31-40 of 276) with videos related to

Sort By:
Pageof 28
Acta Obstetricia Et Gynecologica Scandinavica|November 11, 2009
Para-aortic lymph node metastasis in malignant dysgerminoma of the ovaryBenjamin Kasenda, Philipp Harter, Tobias Hirsch, et al.
Acta Obstetricia Et Gynecologica Scandinavica|October 15, 2009
Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulvaPatriciu Achimas-Cadariu, Philipp Harter, Annette Fisseler-Eckhoff, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 14, 2009
Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center studyRuth Gomez, Philipp Harter, Hans-Joachim Lück, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Cancer Treatment Reviews|July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsHélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 11, 2009
Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinomaStefan Kommoss, Philipp Harter, Alexander Traut, et al.
Gynecologic Oncology|March 19, 2013
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCGFlorian Heitz, Andreas du Bois, Philipp Harter, et al.
ESMO Open|December 14, 2020
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussionSusana Banerjee, Antonio Gonzalez-Martin, Philipp Harter, et al.
Annals of Surgical Oncology|April 2, 2021
Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal CytologyKoji Matsuo, Shinya Matsuzaki, David J Nusbaum, et al.
Investigational New Drugs|September 6, 2013
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)Philipp Harter, Jalid Sehouli, Rainer Kimmig, et al.
Pageof 28